Scientists pinpoint druggable target in aggressive breast cancer
Researchers have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options. Through a comprehensive and cutting-edge genomic screening method known as CRISPR/CAS9 screening, scientists were able to identify a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.
Materials provided by Virginia Commonwealth University. Original written by Blake Belden. Note: Content may be edited for style and length.
Source link aaaaa
